EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 449 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Safety, Tolerability and Antitumour Activity of Lorlatinib in Patients with ALK-Driven... April 7, 2023 Tumors With KRAS G12C Mutation Respond to Adagrasib and Using Toripalimab... April 19, 2023 High Response Rates Observed Following KTE-X19 CAR T-Cell Therapy in Adults... June 15, 2021 Trial Results Support Adding Daratumumab to Initial Treatment for Multiple Myeloma January 19, 2024 Load more HOT NEWS Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... Is That New Lump or Bump a Sarcoma? EMA Recommends Granting a Marketing Authorisation for Lazertinib Enfortumab Vedotin Approved for Recurrent Bladder Cancer
